Institut Claudius Regaud / Oncopole / CHU Toulouse
- Address
- 1 Avenue Irène Joliot Curie, 31059 Toulouse, France
ROS1‑Positive Lung and Solid Tumor Trials
At Institut Claudius Regaud, researchers are advancing therapies for ROS1-positive NSCLC and other solid tumours, focusing on the neoplasm therapeutic area. The current programme tests a highly selective ROS1 inhibitor to define a safe dose and evaluate early signs of tumour response.
- Determination of recommended phase‑2 dose
- Assessment of maximum tolerated dose
- Evaluation of objective response rate in lung cancer
- Exploration of pharmacodynamic biomarkers
- Expansion to multiple solid‑tumour cohorts
The trial brings together three investigators in Toulouse, aiming to expand treatment options for patients with advanced ROS1‑driven cancers.
HER3‑Targeted ADC in Hormone‑Receptor Positive Breast Cancer
The oncology department at the Oncopole is conducting a study in the neoplasm field on HR+/HER2‑negative advanced breast cancer. The investigation evaluates an anti‑HER3 antibody‑drug conjugate to improve outcomes after standard therapies have been exhausted.
- Efficacy assessment of the HER3‑ADC
- Biomarker analyses to predict response
- Safety monitoring in heavily pre‑treated patients
- Impact on progression‑free survival
- Integration of translational research findings
With three investigators leading the effort, the study seeks to offer a novel therapeutic avenue for patients who have limited options after conventional chemotherapy.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Institut Gustave Roussy1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Institut Claudius Regaud / Oncopole / CHU Toulouse
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase 1/2 Evaluation of Zidesamtinib (NVL-520) in Advanced ROS1-Positive NSCLC and Solid Tumors | Nuvalent Inc. | Phase I/II | Recruiting | Feb 2022 | — |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Zidesamtinib | 1 | Unknown | 2022-02-28 | 2022-02-28 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.